Search Results 271-280 of 17854 for Coagulation

  1. A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of Chronic Spontaneous Urticaria in Adults Inadequately Controlled by H1-antihistamines - Mayo Clinic

    - Significant bleeding risk or coagulation disorders - History of gastrointestinal bleeding, e.g. in association with use of nonsteroidal anti-inflammatory ...

  2. Heavy menstrual bleeding - Symptoms and causes - Mayo Clinic

    Some women have menstrual bleeding between periods, or earlier or later in their cycles than expected. This type of bleeding is called abnormal uterine bleeding ...

  3. Study of Pembrolizumab Combined with Decitabine and Pralatrexate in Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma - Mayo Clinic

    > 2.5 mg/dL. Coagulation. International Normalized Ratio (INR) or Prothrombin Time (PT). ≤ 1.5 X ULN unless subject is receiving anticoagulant therapy as ...

  4. Progel Vascular Sealant - Clinical Trials

    Subject has known or suspected preoperative coagulation disorder. Subject is allergic to human thrombin or has a history of allergic reactions after ...

  5. Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer (HOTT) - Mayo Clinic

    Blood coagulation parameters: PT with an INR of ≤ 1.5 and a PTT ≤ 1.5 times the ULN. For patients on full-dose oral anti-coagulation (such as warfarin or ...

  6. Primary sclerosing cholangitis - Doctors and departments - Mayo Clinic

    Liver damage can result from this potentially serious disease in which scarring blocks the bile ducts. A liver transplant is the only known cure.

  7. David M. Menke, M.D. - Doctors and Medical Staff - Mayo Clinic

    DirectorHematopathology and Coagulation Laboratory, St. Luke's Hospital. 1987 - present. MemberAmerican Society for Clinical Pathology. 1983 - 1986. Junior ...

  8. Study of INBRX-109 in Conventional Chondrosarcoma - Mayo Clinic

    Adequate hematologic, coagulation, hepatic and renal function as defined per protocol. 5. Eastern Cooperative Oncology Group performance status (ECOG PS) of ...

  9. Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device - Mayo Clinic

    Uncorrectable abnormal coagulation parameters (platelet count ≤75000/mm3; INR ≥2.0 or fibrinogen ≤1.5 g/l); Active systemic infection requiring treatment ...

  10. Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System - Mayo Clinic

    Subjects with known coagulation disorder (INR ≥ 2 or platelets <50,000). Subjects with hemodynamic instability. Pregnancy (as stated by patient) or breast ...